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Plants or plant cells can be used to produce pharmacological glycoproteins such
as antibodies or vaccines. However these proteins carry N-glycans with plant-
typical residues [β(1,2)-xylose and core α(1,3)-fucose], which can greatly impact the
immunogenicity, allergenicity, or activity of the protein. Two enzymes are responsible
for the addition of plant-specific glycans: β(1,2)-xylosyltransferase (XylT) and α(1,3)-
fucosyltransferase (FucT). Our aim consisted of knocking-out two XylT genes and
four FucT genes (12 alleles altogether) in Nicotiana tabacum BY-2 suspension cells
using CRISPR/Cas9. Three XylT and six FucT sgRNAs were designed to target
conserved regions. After transformation of N. tabacum BY-2 cells with genes coding
for sgRNAs, Cas9, and a selectable marker (bar), transgenic lines were obtained
and their extracellular as well as intracellular protein complements were analyzed by
Western blotting using antibodies recognizing β(1,2)-xylose and α(1,3)-fucose. Three
lines showed a strong reduction of β(1,2)-xylose and α(1,3)-fucose, while two lines
were completely devoid of them, indicating complete gene inactivation. The absence of
these carbohydrates was confirmed by mass spectrometry analysis of the extracellular
proteins. PCR amplification and sequencing of the targeted region indicated small INDEL
and/or deletions between the target sites. The KO lines did not show any particular
morphology and grew as the wild-type. One KO line was transformed with genes
encoding a human IgG2 antibody. The IgG2 expression level was as high as in a
control transformant which had not been glycoengineered. The IgG glycosylation profile
determined by mass spectrometry confirmed that no β(1,2)-xylose or α(1,3)-fucose were
present on the glycosylation moiety and that the dominant glycoform was the GnGn
structure. These data represent an important step toward humanizing the glycosylation
of pharmacological proteins expressed in N. tabacum BY-2 cells.
Keywords: antibody, plant-specific glycans, humanized N-glycosylation, molecular farming, gene editing,
glycoproteins, glyco-engineering, suspension cells
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INTRODUCTION
The production of recombinant proteins in plants (molecular
farming) is seen as an interesting alternative to the current
means of production of biopharmaceutics in microbial and
mammalian cultures. Plants have the advantages of higher
eukaryotes (complex protein folding and post-translational
modifications). Although whole plants have been used intensively
(especially transient expression in Nicotiana benthamiana leaves)
to produce recombinant proteins, the molecular farming field
is very diverse and many different production platforms exist
(Makhzoum et al., 2014). One of them is based on plant
suspension cells. The first example of the production of a
recombinant protein (human albumin) in plant suspension cells
dates back to Sijmons et al. (1990). Plant cell cultures require
a simple and inexpensive growth medium and proteins such
as antibodies can be secreted in the extracellular medium,
facilitating the purification step. Moreover, plant cells are
grown in a contained bioreactor avoiding the regulatory
issues encountered by whole plant production (Santos et al.,
2016).
Plants can perform the N-glycosylation of proteins similarly
to mammalian cells but there are still regulatory issues regarding
the differences between plant and mammalian glycans. Indeed
plants carry core β(1,2)-xylose and core α(1,3)-fucose that are
not present in mammalian glycoproteins. As a consequence,
those residues can possibly elicit an immune or even allergic
response. While the immunogenicity of these residues has
been demonstrated in different studies (Wilson et al., 1998;
van Ree et al., 2000; Altmann, 2007; Bosch et al., 2013),
others did not observe any adverse immune response of
the injected recombinant protein such as the plant-produced
taliglucerase and the influenza virus-like particles (Grabowski
et al., 2014; Ward et al., 2014). Thus, whether the plant
glycans contribute to elicit an immune response or not is
currently unclear. However, for safety and therapeutic efficiency
reasons the immunogenicity needs to be checked for each
particular pharmacological protein during the clinical trial.
A plant-based expression platform expressing recombinant
proteins devoid of any β(1,2)-xylose or α(1,3)-fucose would
be therefore very welcome. Moreover, it would make the
glycosylation more homogenous and potentially more efficient.
For example, it has been shown that an antibody lacking
xylose and fucose produced in silenced N. benthamiana and
carrying β(1,4)-galactose outperformed the same antibody
produced in CHO in a virus neutralization assay (Strasser et al.,
2009).
Two enzymes are responsible for the addition of the plant-
specific glycans: β(1,2)-xylosyltransferase (XylT) and α(1,3)-
fucosyltransferase (FucT) (Strasser et al., 2004). Attempts were
made to remove the plant type glycans by inactivating those
two enzymes. A XylT and FucT knock out mutant has been
reported in Arabidopsis plants (obtained by T-DNA insertion
and crossing) (Strasser et al., 2004) as well as in the moss
Physcomitrella patens (obtained by homologous recombination)
(Huether et al., 2005). RNAi was used to downregulate XylT and
FucT in N. benthamiana (Strasser et al., 2008), Lemnaminor (Cox
et al., 2006), and Medicago sativa (Sourrouille et al., 2008) plants,
as well as in rice (Shin et al., 2011) and Nicotiana tabacum BY-
2 cell lines (Yin et al., 2011). However, the RNAi approach has a
major drawback: inactivation of the expression is never complete.
A genome editing tool to precisely mutate any gene would be
more appropriate. Before the discovery of CRISPR/Cas9 and its
high potential to edit any given gene, there were three classes of
sequence-specific nucleases used to inactivate genes in plants: the
meganucleases, zinc-finger nucleases (ZFNs), and transcription
activator-like effector nucleases (TALENs) (Voytas, 2013). Those
technologies are not straightforward, especially when multiple
genes must be inactivated. A TALEN approach was used very
recently in order to knock-out the XylT and FucT genes in
N. benthamiana plants (Li et al., 2016). Once again, although
significant reduction of β(1,2)-xylose- and core α(1,3)-fucose
was observed, complete loss of both enzymes was not achieved
because not all of the isoforms were targeted.
CRISPR/Cas9 is a new type of sequence-specific nuclease.
It has been shown to be very powerful, versatile, and able to
inactivate multiple genes at the same time (Xie et al., 2015).
Recently, we have shown that the CRISPR/Cas9 nuclease could be
used to inactivate a gene in N. tabacum BY-2 cells (Mercx et al.,
2016). In this study, we identified two XylT and four FucT genes
(12 alleles) and successfully knocked-out these alleles by targeting
conserved regions with CRISPR/Cas9. No trace of β(1,2)-xylose
or α(1,3)-fucose could be detected by Western blotting or
mass spectrometry. A knock-out line was further transformed
for expressing an antibody. These data show that N. tabacum
BY-2 cells can be engineered to humanize pharmacological
glycoproteins produced in this host.
MATERIALS AND METHODS
Plant Cell Cultures
Nicotiana tabacum cv. Bright yellow 2 (BY-2) (Nagata et al., 1992)
suspension cells were grown in the dark at 25◦C with agitation
on a rotary shaker (90 rpm) in liquid MS medium [4.4 g/L
Murashige and Skoog salts (MP BIOMEDICALS, Solon, OH),
30 g/L sucrose, 0.2 g/L KH2PO4, 2.5 mg/L thiamine, 50 mg/ml
myo-inositol, and 0.2 mg/L 2,4-D, pH 5.8 (KOH)]. Cultures were
grown in 50 mL of medium in a 250 mL Erlenmeyer flask and
a 5% inoculum was transferred each week into fresh medium.
Transformed cells were grown on solid medium supplemented
with 15 µg/mL of bialaphos.
XylT and FucT Gene Accessions
Genbank accessions are as follows: XylTA (NM_001324669),
XylTB (NM_001325611), FucTA (XM_016657530), FucTB
(XM_016620229), FucTC (NM_001324945), FucTD (XM_01658
5847).
Cas9 and sgRNA Plasmid Construction
and Plant Cell Transformation
The polycistronic tRNA-gRNA was synthesized (Genescript)
and introduced into a pUC57 vector at the SbfI restriction
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site. The polycistronic sequence was then transferred into the
SbfI cloning site of the pFGC-pcoCas9 binary vector (Li et al.,
2013). The vector was transferred intoAgrobacterium tumefaciens
LBA4404virG (van der Fits et al., 2000) by electroporation.
Transformation of N. tabacum BY-2 cells was performed as
indicated in Mercx et al. (2016). The transgenic KO line 11
(see Results) was further transformed with the binary vector
(pPZP-RCS2-nptII-mCherry-HIgG2-LoBM2) designed for the
production of a human IgG2 antibody (Mercx et al., 2016).
Analysis of Genome Modifications
Genomic DNA was extracted from stable transgenic
transformants after bialaphos selection. PCR was performed
using primers (Supplementary Table S1) flanking the targeted
region. The PCR products were electrophoresed on an ethidium
bromide-stained agarose gel (3%). Bands were extracted,
purified, and cloned into the pGEM-T-easy vector and
sequenced.
SDS-PAGE and Western Blotting
Analysis of Proteins
For extracellular protein glycosylation analysis, 1 mL out of 4 mL
of a 7-day BY-2 culture was filtered on three layers of Miracloth
(Calbiochem) and 30 µL of the filtrate were analyzed by reducing
SDS-PAGE. For extracellular IgG2 production analysis, 1 mL
of a 7-day BY-2 culture in a 50-mL flask was filtered on three
layers of Miracloth (Calbiochem) and 30 µL were analyzed
by non-reducing SDS-PAGE. For the total cellular proteins,
100 mg of solid calli were transferred into a 2 mL Micro tube
(Sarstedt) containing 0.5 g of glass beads (0.85–1.23 mm) and
800 µL of homogenization buffer (250 mM sorbitol, 60 mM
Tris–HCl, 2 mM Na2EDTA, pH 8.0) supplemented with 5 mM
DTT, 1 mM phenylmethylsulfonylfluoride (PMSF), and protease
inhibitor cocktail (leupeptin, aprotinin, antipain, pepstain, and
chymostain, each at 2 µg/mL). Cell grinding was performed
for 3 × 40 s at 5000 rpm (PrecellysTm24 Control Device
Bertin Technologies) with 2 min pauses on ice. The samples
were centrifuged for 10 min at 10,000 g (Eppendorf 5417C).
The protein concentration in the supernatant was quantified
and 15 µg of proteins were analyzed by SDS-PAGE (4–20%
polyacrylamide) and either stained with Coomassie Brilliant
Blue G-250 (SERVA, Heidelberg, Germany) or transferred
onto a PVDF membrane (Millipore, Billerica, MA, USA) for
Western blotting analysis. The PVDF membrane was incubated
with the primary antibodies against β(1,2)-xylose (monoclonal
antibody, Agrisera AS07 267; dilution 1:5,000) or α(1,3)-fucose
(monoclonal antibody, Agrisera AS07 268: dilution 1:10,000),
and then with the secondary HRP-conjugated antibodies against
rabbit IgG (dilution 1:10,000). The signals were quantified
using a Kodak Image Station 4000R (Eastman Kodak company,
Rochester, NY, USA).
Mass Spectrometry Analysis of Total
N-glycans of the Secreted Proteins
Fifty mL of a 7-day old BY-2 suspension culture was filtered
on three layers of Miracloth (Calbiochem) and 10 mL aliquots
of the filtrate were centrifuged (8,000 g, 30 min) and the
supernatant was concentrated to 1 mL using Amicon R© Ultra-4
centrifugal filter units, MWCO 3 kDa (Millipore). The proteins
were precipitated by salting-out using (NH4)2SO4 (35% w/w,
incubated on ice for 30 min after complete dissolution). The
samples were then centrifuged for 10 min at 16,000 g and
the supernatant was discarded. The pellet was solubilized in
50 mM NH4HCO3 and the proteins were reduced (incubation
with 10 mM DTT, 56◦C, 40 min) and alkylated (20 mM
iodoacetamide, 20◦C, 30 min). Additional purification was then
performed using a 2D Clean-up Kit (GE Healthcare). The
proteins were resuspended in 50 mM NH4HCO3 and digested
using trypsin (first incubation at 1/50 (w/w) for 16 h at
37◦C followed by a second incubation with 1/100 additional
trypsin for 3 h in 80% acetonitrile at 37◦C). After heat
inactivation of trypsin and solvent evaporation, the peptides
were resuspended in citrate-phosphate buffer (48.3 mM citric
acid, 103.3 mM Na2HPO4, pH 5) and the N-glycans were
released using PNGase A (0.2 mU/100 µg, 24 h at 37◦C).
Digestion was stopped by the addition of trifluoroacetic acid
(0.5%). The N-glycans were separated from the peptide using
Sep-Pack C18 cartridges (Waters) using a 1-propanol/5% acetic
acid system. TheN-glycans were then desalted using a Glycoclean
H-cartridge (Prozyme) and evaporated to dryness. Next, they
were resuspended in labeling solution (750 mM NaBH3CN,
175 mM 2-aminobenzidine in DMSO/acetic acid at a 10:3 ratio)
and incubated at 65◦C for 2 h. Purification on a Glycoclean
S-cartridge (Prozyme) was finally performed according to the
manufacturer’s protocol and the N-glycans were evaporated to
dryness.
Before mass spectrometry analysis, the glycans were
resuspended in 10 µL 50% acetonitrile. One microlliter
of sample was mixed on a MALDI plate with 1 µL of
matrix (2,5 dihydroxybenzoic acid prepared at 20 mg/mL
in water/acetonitrile 50/50, 0.1% formic acid) and allowed to
dry. For every sample, 10 mass spectra were recorded on a
MALDI-TOF instrument (Ultraflextreme, Bruker Daltonics) by
adding 5000 laser shots.
The data were analyzed using FlexAnalysis 3.4 software
(Bruker Daltonics). The intensities of the glycan peaks
were normalized to the total glycan signal allowing relative
proportions to be determined. The detected peaks were
annotated using GlycoWorkbench 2.
Purification of IgG
Eight× 50 mL of a 7-day old BY-2 suspension culture was filtered
on three layers of Miracloth (Calbiochem) and the filtrate was
centrifuged (8,000 g, 30 min). The supernatant was recovered,
supplemented with 10% 1 M Tris-Cl pH 8.0 and incubated for
16 h at 4◦C with one mL of Pierce R© Protein A Plus Agarose
(Thermoscientific # 22812) previously washed three times with
10 mL of 0.1 M Tris-Cl pH 8.0. The sample was then filtered
through a nylon membrane and poured onto a poly-prep R©
chromatography column (Biorad # 731-1550). After washing
with 10 mL of 0.1 M Tris-Cl pH 8.0, IgG were eluted with
8 × 500 µL 0.1 M glycin pH 3.0 and immediately supplemented
with 10% 1 M Tris-Cl pH 8.0. Ten microlliter of each elution
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fraction were used for SDS-PAGE (8% acrylamide) analysis
followed by colloidal blue staining.
Mass Spectrometry Analysis of IgG
Glycosylation
The IgG sample was submitted to proteolysis as described
above and in Navarre et al. (2017). The resulting (glyco)peptides
were separated by reverse-phase chromatography using
UPLC (MClass, HSS T3 column, Waters) in one dimension
with an increasing ratio of acetonitrile/water (5–40% for
70 min) at a 600 nL/min flow rate. It was coupled to a Hybrid
Quadrupole-Orbitrap Mass Spectrometer (Q-Exactive Plus,
Thermo Fisher Scientific, USA), programmed for data-
dependent acquisition mode. Survey scans were acquired at
70,000 mass resolving power (full width at half maximum).
An ion mass range from 400 to 1600 m/z was acquired in MS
mode, and 3E6 ions were accumulated in the survey scans.
Ion trap Higher energy Collision Dissociation fragmentations
at NCE 28 were performed within 1.6 amu isolation windows
and a dynamic exclusion was enabled for 10 s. MS/MS
spectra were searched for typical oxonium ions (m/z 204.09
and 366.14) indicating the presence of glycopeptides.
The presence of Y1 ion (m/z 1360.60 corresponding to
EEQFN∗STFR where ∗ = HexNAc) was also checked to
confirm the glycosylation site. For the assigned spectra, the
composition of the glycopeptides was determined based on
their precursor mass using the Glycomod tool (available at
http://web.expasy.org/glycomod/) and their MS/MS spectra.
Following that step, the relative abundance of the glycopeptides
was determined by integration of MS1 chromatograms using
Skyline 3.1.
RESULTS
In N. tabacum the XylT and the FucT genes have not
been annotated yet. N. tabacum is an allotetraploid resulting
from a cross between Nicotiana sylvestris and Nicotiana
FIGURE 1 | DNA constructs aimed at inactivating the XylT and FucT genes. (A) Schematic representation of the XylT and FucT genes. Black boxes and lines
represent exons and introns, respectively. Arrows indicate the target sites for CRISPR-Cas9 as detailed in (B). (B) Sequence of the XylT and FucT target sites for
CRISPR-Cas9. The sequences of the two XylT (A,B) and the four FucT (A–D) genes is compared. Stars indicate conserved positions. The red, orange, and brown
sequences correspond to the XylT sgRNAs. The green, blue, and violet sequences correspond to the FucT sgRNAs. For FucT, a divergent sequence is italicized.
The PAM sequence is in bold. (C) Schematic representation of the binary vector pFGC-Cas9-tRNA-sgRNAXylT(3)–sgRNAFucT(6). Left (LB) and right (RB) T-DNA
borders are indicated. The Cas9 gene is controlled by the 35S-PPDK transcriptional promoter. The synthetic polycistronic tRNA-gRNA consists of tandemly arrayed
tRNA-gRNA units downstream of the U6 transcriptional promoter. A bar gene permits the selection of transformants.
Frontiers in Plant Science | www.frontiersin.org 4 March 2017 | Volume 8 | Article 403
fpls-08-00403 March 23, 2017 Time: 15:31 # 5
Mercx et al. Inactivation β(1,2)-xylosyltransferase α(1,3)-fucosyltransferase BY-2 Cells
tomentosiformis and is thus expected to contain at least two
sets of genes. We retrieved and aligned the coding sequences
corresponding to putative XylT and FucT genes of three
cultivars (TN90, BX, and K326) whose genomic sequences
had been deposited on the Sol Genomics Network1 as well
as on NCBI. For XylT we found two isoforms, one from
N. sylvestris (XylTA: Ntab-TN90_AYMY-SS628) and one from
N. tomentosiformis (XylTB: Ntab-TN90_AYMY-SS11650). For
FucT we found four isoforms: two from N. sylvestris (FucTA:
Ntab-TN90_AYMY-SS18207; FucTD: CDS-Ntab-TN90_AYMY-
SS18127) and two from N. tomentosiformis (FucTB: Ntab-
TN90_AYMY-SS18046; FucTC: Ntab-TN90_AYMY-SS15344).
Genbank accession numbers for XylT and FucT mRNA
1https://solgenomics.net/organism/Nicotiana_tabacum/genome
annotations can be found in Section “Materials and Methods.”
Unlike plants, suspension cells cannot be self-crossed to obtain
homozygous mutants. Altogether, 12 target genes were selected
for inactivation. To increase the likelihood of mutating all of
them, we targeted the most conserved regions of the genes so that
one sgRNA could target a maximum of isoforms. Therefore, three
sgRNAs were designed to target three conserved regions of XylT
exon 1 (where the two XylT genes are identical), and six sgRNAs
were designed to target three conserved regions of FucT exon 3
(where the four genes group into two sequences) (Figures 1A,B).
To assemble the sgRNA coding sequences we used the
multiplex strategy in which a tRNA is positioned after each
sgRNA and a U6 promoter is located upstream of the polycistron
(Xie et al., 2015) (Figure 1C). The scaffold of the sgRNA
was optimized to increase the targeting efficiency as proposed
FIGURE 2 | Absence of α(1,3)-fucose and β(1,2)-xylose on glycoproteins from the XylT and FucT KO lines. Secreted proteins (30 µl culture medium) (A) or
total cellular proteins (15 µg) (B) from a WT and the indicated pFGC-Cas9-tRNA-sgRNA(9) transgenic lines were electrophoresed and analyzed by Western blotting
using antibodies against β(1,2)-xylose and α(1,3)-fucose, A colloidal blue gel is displayed below as a loading control.
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by Dang et al. (2015). The whole cassette was inserted into
the pFGC-Cas9 binary vector containing the Cas9 gene and
a bar gene for selection (Figure 1C). After transformation
of N. tabacum BY-2 cells with A. tumefaciens and selection
on bialaphos, 28 transgenic lines were obtained and 10 were
analyzed in more detail. The proteins secreted in the culture
medium and the total cellular proteins were analyzed by Western
blotting using antibodies recognizing β(1,2)-xylose and α(1,3)-
fucose (Figure 2). Three lines (2, 23, 26) showed a strong
reduction of β(1,2)-xylose and α(1,3)-fucose, while two lines (11,
12) were completely devoid of them, indicating complete gene
inactivation.
TABLE 1 | Relative amount of total N-glycans (%) of the extracellular proteins of line 11, line 12 and Wt.
Lines
m/z Composition Proposed structure Abbreviation∗ 11 12 WT
1459,6 HexNAc4Hex3 GnGn 39,9 44,6 n.d.
1256,53 HexNAc3Hex3 GnM 41,1 39,1 n.d.
1331,586 HexNAc2Hex3dHex1Pent1 MMXF n.d. n.d. 31,5
1534,67 HexNAc3Hex3dHex1Pent1 GnMXF n.d. n.d. 42,4
1737,776 HexNAc4Hex3dHex1Pent1 GnGnXF n.d. n.d. 8,5
1053,441 HexNAc2Hex3 MM 6,4 4,8 n.d.
1539,6 HexNAc2Hex6 3,4 3,1 3,7
1388,6 HexNAc3Hex3Pent1 n.d. n.d. 3,4
1701,657 HexNAc2Hex7 2,9 2,6 1,8
1185,518 HexNAc2Hex3Pent1 n.d. n.d. 2,6
1377,55 HexNAc2Hex5 1,3 1,1 1,7
1169,524 HexNAc2Hex2dHex1Pent1 n.d. n.d. 1,3
2025,763 HexNAc2Hex9 1,5 1,3 0,8
1863,709 HexNAc2Hex8 1,4 1,3 0,9
1094,471 HexNAc3Hex2 0,8 0,8 n.d.
1767,7 HexNAc4Hex4dHex1 0,8 0,7 n.d.
891,37 HexNAc2Hex2 0,6 0,7 n.d.
2045,878 HexNAc4Hex4dHex2Pent1 n.d. n.d. 0,5
1591,697 HexNAc4Hex3Pent1 n.d. n.d. 0,5
1037,47 HexNAc2Hex2dHex1 n.d. n.d. 0,2
1696,7 HexNAc3Hex4dHex1Pent1 n.d. n.d. 0,2
1899,786 HexNAc4Hex4dHex1Pent1 n.d. n.d. 0,1
2354,006 HexNAc4Hex5dHex3Pent1 n.d. n.d. < 0,1
∗According to the nomenclature (Proglycan short) from http://www.proglycan.com/. Gn, N-Acétylglucosamine; M/Man, mannose; X, xylose; F, fucose.
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MALDI-TOF MS analysis was performed to investigate the
glycoform profile of the secreted proteins from lines 11 and
12. The structures of the total N-Glycans are presented in
Table 1. The results confirm that no β(1,2)-xylose and no α(1,3)-
fucose are present on the glycan moieties for lines 11 and 12,
unlike the wild-type (WT) line in which more than 91% of
the N-glycans carry a β(1,2)-xylose and more than 83% carry
a α(1,3)-fucose residue. There is, however, one glycoform in
the KO lines that carries a fucose (less than 0.8%), which most
likely belongs to the Lewis epitope. Indeed, MS/MS analysis
revealed a peak at 1222,794 m/z that corresponds to a Lewis
epitope fragment (Supplementary Figure S2). In more detail
(shown for line 11 and WT in Supplementary Figures S1–S3),
the mass spectrum for lines 11 and 12 showed that GnM
(41.1 and 39.1% of the total N-glycans, respectively) and GnGn
structures (39.9 and 44.6% of the total N-glycans, respectively)
are the most abundant and represent more than 80% of the
total N-glycans. Several high-mannose type glycans are also
present as well as the MM structure. In comparison, the WT line
showed that the GnMXF, MMXF, GnGnXF structures (42.4%;
31.4%; 8.5% of the total N-glycans) are the most abundant
glycoforms.
We sought to determine the modifications that occurred in the
FucT and XylT loci. PCR amplification with primers hybridizing
to conserved regions (Supplementary Table S1) of the XylT
or FucT target region was performed. Electrophoresis analysis
showed shortened fragments (Figure 3A) (corresponding to
deletions) for lines 11 and 12 between two target sites, for
both XylT and FucT. For line 11, the amplicons for FucT
and XylT were cloned into pGEM-T Easy and sequenced. In
total, we retrieved 36 sequences for FucT and seven for XylT,
which resulted in six different sequences for FucT and four for
XylT (Figure 3B). The sequencing results confirmed that small
INDEL’s and deletions between the target sites took place.
The KO lines did not display any particular phenotype and
grew as WT cells. To demonstrate that a KO line can be used
for expressing an ectopic protein, we transformed the KO line
11 with a binary vector (pPZP-RCS2-nptII-mCherry-HIgG2-
LoBM2) designed for the production of a human IgG2 antibody
(Mercx et al., 2016). The expression of the antibody was checked
FIGURE 3 | (A) PCR amplification of the XylT and FucT target regions. Genomic DNA prepared from the WT and the indicated transgenic lines was used to amplify
the XylT and FucT target regions. (B) Sequences of the target regions in the PCR fragments. XylTA, B and FucTA-D: WT sequences; 1-6: sequences of line 11.
Frontiers in Plant Science | www.frontiersin.org 7 March 2017 | Volume 8 | Article 403
fpls-08-00403 March 23, 2017 Time: 15:31 # 8
Mercx et al. Inactivation β(1,2)-xylosyltransferase α(1,3)-fucosyltransferase BY-2 Cells
FIGURE 4 | Expression of human IgG2 in the XylT/FucT KO line 11. The
extracellular medium (30 µL) of five kanamycin resistant lines was analyzed by
non-reducing SDS-PAGE followed by colloidal blue staining. The lane on the
right hand side shows the peak elution fraction of the purified antibody.
Arrowhead indicates the band corresponding to the IgG2.
in five kanamycin resistant lines. The extracellular medium of
7-day old cultures was analyzed by non-reducing SDS-PAGE
(Figure 4). As a control, we also analyzed the SC6 transgenic
line that had been previously obtained with the same antibody-
encoding binary vector (Mercx et al., 2016). The intensity of the
band corresponding to the intact antibody for lines 11/1 and 11/5
were as high as for the control SC6 transgenic line, meaning that
the antibody production rate in the KO line was not affected. We
then purified the antibody from line 11/5 grown in eight 50 mL-
Erlenmeyer flasks for 7 days (Figure 4). The glycosylation profile
was checked by mass spectrometry (Table 2). As expected, no
β(1,2)-xylose or α(1,3)-fucose residues were identified on the IgG
expressed in the KO line. The major structure in the KO line
11/5 was GnGn (69%). The second major structure was Man7
representing 9.3% and several other high-mannose type glycans
as well as GnM were also identified.
DISCUSSION
In this work, we took advantage of the recent development of
CRISPR/Cas9 and its easiness to target multiple sequences to
inactivate the XylT and FucT genes.
We identified two XylT and four FucT isoforms, and a total
of 12 loci were disrupted. While this article was under review,
Hanania et al. (2017) published a very similar study inactivating
the β(1,2)-xylosyltransferase and the α(1,3)-fucosyltransferase
genes in N. tabacum BY-2 cells with CRISPR/Cas9. These authors
mentioned that five FucT genes were inactivated. We figured out
that the isoform called FucT-B (Ntab-BX_AWOK-SS16887) by
Hanania et al. (2017) is only present in one out of three cultivars
(in BX and not in TN90 and K326) and is identical to FucTD
TABLE 2 | Relative amount of N-glycans (%) on the IgG secreted in the KO line 11/5.
Composition Proposed structure Abbreviation∗ Percentage
EEQFNSTFR-HexNAc4Hex3 GnGn 69,0
EEQFNSTFR-HexNAc2Hex7 Man7 9,3
EEQFNSTFR-HexNAc3Hex3 GnM 4,8
EEQFNSTFR-HexNAc2Hex6 4,3
EEQFNSTFR-HexNAc2Hex8 3,4
EEQFNSTFR-HexNAc2Hex5 3,2
EEQFNSTFR-HexNAc3Hex5 2,0
EEQFNSTFR-HexNAc3Hex4 2,0
EEQFNSTFR-HexNAc3Hex2 0,6
EEQFNSTFR-HexNAc3Hex6 0,5
EEQFNSTFR-HexNAc4Hex4 0,5
EEQFNSTFR-HexNAc2Hex4 0,2
EEQFNSTFR-HexNAc2Hex3 < 0,1
EEQFNSTFR-HexNAc2Hex9 < 0,1
∗According to the nomenclature (Proglycan short) from http://www.proglycan.com/. Gn, N-Acétylglucosamine; M/Man, Mannose; X, Xylose; F, Fucose.
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(called FucT-A in Hanania et al., 2017) in the 5′ region and
identical to FucTC (called FucT-C in Hanania et al., 2017) in the
3′ region. This gene might therefore have arisen in one cultivar
by recombination or might be a sequence assembly artifact. In
this study we chose three conserved regions for each target. For
XylT, a single sgRNA per region was sufficient to target the
two isoforms, but for FucT, we were unable to find a 20 bp
conserved region near a PAM sequence for the four isoforms.
Thus, two sgRNAs were designed for each target region. Editing
was quite efficient since, in each sequence we retrieved from FucT,
mutations occurred in at least two of the three targets. For XylT,
among the four mutated sequences obtained, three were mutated
in at least two target sites, and only one at a single site. The
efficiency of targeting can be explained by the fact that Cas9
and the sgRNAs are stably integrated into the genome and are
continuously expressed. A drawback of the CRISPR-Cas9 editing
system is that, although rare, off-targets might be generated
(Puchta, 2016). However, after fifteen transfers, the transgenic
lines looked fine and grew similar to the WT.
Because the N. tabacum genome is not fully sequenced, nor
annotated, we cannot rule out that a still unknown XylT or FucT
gene was not targeted by the CRISPR-Cas9 approach. However,
in this case its expression in BY-2 cells must be below detection
since the Western blotting analysis did not show any residual
signal neither for the anti-α(1,3)-fucose nor for the anti-xylose
antibody. The N-glycans analysis by MALDI-TOF showed that
lines 11 and 12 do not display detectable β(1,2)-xylose and α(1,3)-
fucose unlike the WT line, for which more than 91% of the
N-glycans carry a β(1,2)-xylose and more than 83% carry a
α(1,3)-fucose residue. Several high-mannose type glycans are also
present. This is in agreement with a study from Misaki et al.
(2001), which showed that these high-rich mannose N-glycans
are present on secreted proteins from N. tabacum BY-2 cells.
One advantage of plants compared to animal platform
production is the homogeneity of glycosylation. Here we
confirmed that glycosylation of the secreted proteins is quite
homogenous with more than 80% of the total N-glycans being
either GnMXF (42.4%), MMXF (31.5%), or GnGnXF (8.5%) for
the WT line. Interestingly lines 11 and 12 still improved this
homogeneity with more than 87% of the total N-glycans being
either GnGn (39.9-44.6%), GnM (41.1-39.1%) or MM (6.4-4.8%).
We can point out that the paucimannosidic N-glycans are
much less present in the KO lines (Table 1). This correlates
with a recent study (Shin et al., 2016) that demonstrated that
in N. benthamiana, the presence of the core α(1,3)-fucose on
the N-glycans enhances the trimming of GlcNAc residues. These
authors showed that this trimming is due to the activity of
β-hexosaminidases, mainly located in the plasma membrane
in leaf epidermal cells. Paucimannosidic N-glycans increase
the heterogeneity of the therapeutic product and may affect
the biological activity of the recombinant protein. Thus, by
expressing a recombinant protein in these XylT/FucT KO lines
we should increase the homogeneity of the glycosylation profile
and reduce the unwanted truncated N-glycans.
The expression level of an antibody in a XylT/FucT KO line
was similar as that in a FucT and XylT wild-type line. Knocking-
out these genes is therefore not detrimental to the expression of
an ectopic protein. The glycosylation profile of the IgG secreted in
the XylT/FucT KO line was consistent with the profile identified
for the total N-glycans of the secreted proteins. However, a lower
amount of paucimannosidic structures was identified for the
IgG compared to the total secreted proteins. This is probably
because the antibody glycosylation site is little accessible for
β-hexosaminidases.
Plant specific glycans, especially β(1,2)-xylose and α(1,3)-
fucose, have been for years a real hurdle for the regulatory
approval of recombinant proteins expressed in plants (Santos
et al., 2016). Here, we provide an expression platform that
possesses all of the conditions to produce recombinant proteins
under GMP with no regulatory issues. Indeed, plant suspension
cells can be grown in contained bioreactors similar to the
current mammalian production platform, and thus do not
suffer from the absence of regulatory pathways such as for
whole plant production. Compared to mammalian production
platforms such as Chinese hamster ovary (CHO) cells, plant
cells have two main advantages: they cannot be contaminated
with animal pathogens (e.g., viruses or prions) and the culture
medium is particularly cheap. On the negative side, plant cells
still have a lower production rate (e.g., 30–100 mg IgG/ml;
Vasilev et al., 2013; Magy et al., 2014) while CHO cells can
produce more than 1 g/L (Kunert and Reinhart, 2016). However,
the production in plant cells has not yet benefited from the
long research history that characterizes animal cells and yield
improvement can be expected at different levels such as fed-
batch strategies, elite line selection, gene amplification, inhibition
of proteolytic activity, medium optimization (Santos et al.,
2016).
Besides cell suspensions, Agrobacterium- or virus-mediated
transient expression in leaf tissues is another interesting plant
production system. It is cheap, fast and can be easily up-scaled.
A production yield of 1 mg of rituximab antibody per gram
leaf (fresh weight) has been reported (Diamos et al., 2016).
However, down-stream processing (e.g., purification) represents
an important part of the production costs which should be
lower with suspension cells when the protein of interest is
secreted. Indeed, in this case the protein has to be purified
from the external medium which is less complex in the absence
of plant fibers and a range of secondary metabolites and
proteins than a total leaf extract (Yao et al., 2015). In addition,
confinement and reproducibility are better controlled in stable
cell suspension cultures. Now that potential immunogenic and/or
allergic residues have been removed, no additional regulatory
issues could prevent the emergence of plant cell-produced
recombinant proteins onto the market.
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